NuCana PLC (NCNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NuCana PLC (NCNA) has a cash flow conversion efficiency ratio of -0.038x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-930.00K) by net assets ($24.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NuCana PLC (NCNA) net asset quality to measure how much of total assets are equity-financed.
NuCana PLC - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how NuCana PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does NuCana PLC reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
NuCana PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NuCana PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Dixie Group Inc
NASDAQ:DXYN
|
-0.035x |
|
Predilife
PA:ALPRE
|
0.219x |
|
TOP Ships Inc.
NYSE MKT:TOPS
|
0.081x |
|
ConnectM Technology Solutions, Inc.
NASDAQ:CNTM
|
0.098x |
|
Cahaya Bintang Medan Tbk Pt
JK:CBMF
|
0.000x |
|
Brilliant Future AB
ST:BRILL
|
-0.207x |
|
Power Line Engineering Public Company Limited
BK:PLE
|
0.243x |
|
D.T.C. Industries Public Company Limited
BK:DTCI
|
0.010x |
Annual Cash Flow Conversion Efficiency for NuCana PLC (2014–2025)
The table below shows the annual cash flow conversion efficiency of NuCana PLC from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see NCNA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.28 Million | $-6.96 Million | -0.287x | +91.08% |
| 2024-12-31 | $5.95 Million | $-19.12 Million | -3.211x | -80.80% |
| 2023-12-31 | $14.89 Million | $-26.44 Million | -1.776x | -195.27% |
| 2022-12-31 | $38.50 Million | $-23.16 Million | -0.601x | -65.49% |
| 2021-12-31 | $65.55 Million | $-23.82 Million | -0.363x | -66.83% |
| 2020-12-31 | $99.23 Million | $-21.62 Million | -0.218x | +41.93% |
| 2019-12-31 | $63.52 Million | $-23.83 Million | -0.375x | -150.44% |
| 2018-12-31 | $81.59 Million | $-12.22 Million | -0.150x | -60.72% |
| 2017-12-31 | $93.42 Million | $-8.71 Million | -0.093x | +74.60% |
| 2016-12-31 | $25.24 Million | $-9.26 Million | -0.367x | -146.16% |
| 2015-12-31 | $29.96 Million | $-4.47 Million | -0.149x | +99.90% |
| 2014-12-31 | $34.51K | $-5.25 Million | -151.998x | -- |
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metab… Read more